Peripartum cardiomyopathy: diagnosis and treatment

Peripartum cardiomyopathy is an uncommon but potentially life-threatening form of heart failure associated with pregnancy and the months after delivery. It can appear late in pregnancy or during the postpartum period, when breathlessness, swelling, fatigue, and rapid heartbeat may be mistaken for normal changes of pregnancy or recovery from childbirth.

The condition involves reduced contraction of the left ventricle, the heart’s main pumping chamber. Diagnosis requires evidence of left ventricular systolic dysfunction, usually an ejection fraction below 45%, without another clear cause of heart failure. Early recognition matters because treatment can improve symptoms, protect organ function, and increase the chance of recovery.

Perinatal medicine depends on close coordination between obstetric, neonatal, cardiology, and critical care teams. The archived congress resources associated with FAOPS 2020 reflect the international focus on perinatal and neonatal research, an area in which awareness of maternal cardiovascular disease remains essential.

Why this condition is often missed

Pregnancy normally increases blood volume, heart rate, and cardiac output. Shortness of breath during exertion, mild ankle swelling, tiredness, and difficulty sleeping may therefore appear routine. In peripartum cardiomyopathy, however, symptoms tend to become progressive, occur at rest, or interfere with lying flat and ordinary activity.

Warning signs include breathlessness when lying down, waking suddenly gasping for air, rapid weight gain from fluid retention, persistent cough, chest discomfort, fainting, marked palpitations, and swelling extending beyond the ankles. A woman who feels unable to complete familiar activities or who has worsening symptoms after delivery requires prompt assessment rather than reassurance alone.

Risk is higher with pre-eclampsia or gestational hypertension, multiple pregnancy, advanced maternal age, a history of cardiomyopathy, African or Afro-Caribbean ancestry, and certain medications or medical conditions. These factors do not establish a diagnosis, and many patients have no recognized risk factor. Clinical vigilance is therefore necessary for every pregnancy and postpartum patient.

Establishing the diagnosis

Assessment starts with vital signs, oxygen saturation, cardiac and lung examination, fluid balance, and an electrocardiogram. A chest X-ray may show pulmonary congestion or an enlarged cardiac silhouette, although a normal image does not exclude early disease. Blood tests commonly include a complete blood count, kidney and liver function, electrolytes, thyroid tests, and cardiac biomarkers.

B-type natriuretic peptide or N-terminal pro-BNP can support the diagnosis because these markers rise when the heart is under pressure. They should be interpreted in context, since pregnancy and other illnesses can affect results. Troponin may be elevated when there is myocardial injury, but it is not required for the diagnosis.

Echocardiography is the central test. It measures left ventricular ejection fraction, chamber size, wall motion, right ventricular function, valve performance, and pulmonary pressures. It can also identify intracardiac thrombus. A reduced ejection fraction with no alternative explanation supports peripartum cardiomyopathy, while regional abnormalities, severe valve disease, or congenital defects may point toward another cause.

Cardiac magnetic resonance imaging can provide additional information when myocarditis, infiltrative disease, scar, or another cardiomyopathy is suspected. Coronary disease, pulmonary embolism, infection, severe anemia, thyroid disease, and hypertensive heart disease must also be considered. A careful medication and family history helps identify toxic, genetic, or previously unrecognized cardiac disorders.

Distinguishing common causes of breathlessness

Symptoms alone cannot reliably separate normal pregnancy changes from serious cardiovascular disease. The pattern, severity, examination findings, and objective tests must be considered together. Sudden pleuritic pain, low oxygen saturation, coughing blood, or an unexplained fast heart rate may suggest pulmonary embolism and require an urgent diagnostic pathway.

Myocarditis can resemble peripartum cardiomyopathy and may be associated with chest pain, fever, rhythm abnormalities, or a recent viral illness. Acute coronary syndrome is less common in young patients but can occur during pregnancy and after delivery. Severe hypertension with headache, visual symptoms, or upper abdominal pain raises concern for pre-eclampsia-related cardiac dysfunction.

The timing of symptoms is helpful but not definitive. Although the classic definition places onset toward the end of pregnancy or within several months after delivery, cases may be recognized later, especially when early symptoms were attributed to postpartum exhaustion. Any unexplained heart failure in this period deserves consideration of a pregnancy-associated cause.

Stabilizing acute heart failure

Patients with pulmonary edema, low blood pressure, severe oxygen deficiency, confusion, reduced urine output, or rapidly worsening symptoms need emergency hospital care. Initial treatment includes positioning, oxygen when indicated, careful fluid management, and intravenous loop diuretics for congestion. Excessive fluid administration can worsen pulmonary edema and should be avoided unless there is a clear reason.

During pregnancy, treatment must protect both mother and fetus. Beta blockers may be used when clinically appropriate, with selection and dosing guided by maternal condition and fetal considerations. Vasodilators such as hydralazine and nitrates can help reduce cardiac workload when blood pressure permits. ACE inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors are generally avoided during pregnancy because of fetal or limited safety concerns.

After delivery, guideline-directed heart failure therapy can usually be expanded. An ACE inhibitor such as enalapril is commonly considered compatible with breastfeeding, while medication choice should be reviewed individually. Beta blockers, diuretics, and mineralocorticoid receptor antagonists may also be used with attention to maternal blood pressure, kidney function, electrolytes, and milk production.

Cardiogenic shock requires intensive care and early involvement of a heart failure team. Inotropes or vasopressors may be necessary, and temporary mechanical circulatory support can be considered when medication cannot maintain circulation. Decisions about delivery in a critically ill pregnant patient require coordinated maternal-fetal medicine, cardiology, anesthesia, neonatology, and critical care expertise.

Reducing clot and rhythm complications

A weakened, enlarged ventricle can allow blood to stagnate, increasing the risk of left ventricular thrombus and systemic embolism. Anticoagulation is not automatic for every patient with peripartum cardiomyopathy. It may be considered when there is a visible ventricular clot, atrial fibrillation, previous embolism, very low ejection fraction, or treatment with bromocriptine.

Pregnancy, childbirth, and the postpartum period already alter clotting risk, so decisions must balance embolic risk against bleeding risk. Low-molecular-weight heparin is often preferred during pregnancy when anticoagulation is needed. After delivery, warfarin or selected direct oral anticoagulants may be considered according to breastfeeding status, renal function, drug interactions, and specialist advice.

Life-threatening ventricular arrhythmias can occur when systolic function is severely reduced. Correcting potassium and magnesium abnormalities, treating congestion, and using appropriate heart failure therapy can lower risk. A wearable defibrillator may be discussed temporarily in selected patients while ventricular recovery is assessed. Permanent implantable defibrillator decisions are generally deferred until after a period of optimized treatment unless there is a separate strong indication.

Bromocriptine, which suppresses prolactin, has been studied as a disease-specific treatment. Evidence remains mixed, and it stops lactation while potentially increasing thrombotic risk. If used, it should be part of a specialist protocol that includes careful anticoagulation assessment rather than a routine treatment for all patients.

Recovery, follow-up, and future pregnancy

Left ventricular function may improve substantially during the first several months after diagnosis, but recovery is variable. Improvement in ejection fraction does not always mean that the heart has returned to normal, and symptoms can recur if medication is stopped too quickly. Repeat echocardiography is important, often at intervals selected by the treating cardiologist.

Long-term care includes blood pressure control, gradual physical rehabilitation, nutrition counseling, vaccination where appropriate, and review of sleep and mental health. Persistent fatigue or anxiety after a difficult pregnancy should be taken seriously. Depression, fear of another pregnancy, and the demands of caring for a newborn can interfere with medication adherence and follow-up.

Future pregnancy requires individualized counseling before conception. A pregnancy may carry substantial risk when ejection fraction remains reduced, ventricular dimensions are abnormal, or symptoms persist. Even after apparent recovery, relapse can occur. Reliable contraception and preconception evaluation allow medication changes to be made safely and provide time to discuss maternal and fetal risks.

Families may benefit from genetic assessment when there is a personal or family history of cardiomyopathy, sudden cardiac death, unexplained heart failure, or repeated pregnancy-associated disease. First-degree relatives may need screening. Clear discharge instructions should identify symptoms that require urgent help, including breathlessness at rest, fainting, chest pain, rapid swelling, confusion, or a sudden decline in exercise tolerance.

Practical steps for safer care

Effective management depends on recognizing deterioration early and ensuring that care continues after discharge. Patients and families should receive a written plan that explains medication timing, weight monitoring, follow-up appointments, breastfeeding considerations, and emergency symptoms.

Clinicians caring for pregnant or postpartum patients can strengthen safety by:

• Checking for orthopnea, nighttime breathlessness, persistent tachycardia, and rapid fluid-related weight gain rather than attributing every symptom to pregnancy.
• Arranging urgent echocardiography and natriuretic peptide testing when heart failure is suspected.
• Avoiding contraindicated renin-angiotensin system medicines during pregnancy and reviewing all prescriptions after delivery.
• Coordinating cardiology, maternal-fetal medicine, neonatology, pharmacy, anesthesia, and primary care follow-up.
• Documenting ventricular recovery, anticoagulation decisions, contraception counseling, and the plan for any future pregnancy.

A structured transition from hospital to home is particularly important. The first weeks after birth can involve changing blood pressure, interrupted sleep, feeding challenges, and limited access to transportation. Telephone follow-up, home monitoring, and involvement of a support person may help identify worsening congestion before it becomes an emergency.

Peripartum cardiomyopathy should be treated as a time-sensitive cardiovascular disorder, not as an unavoidable feature of late pregnancy or new parenthood. Prompt assessment, evidence-based heart failure therapy, careful anticoagulation decisions, and long-term cardiology surveillance can change the course of illness. Anyone with concerning symptoms should seek urgent medical evaluation, and healthcare teams should act quickly when postpartum heart failure is suspected.